Financial News
Articles published by Incyte
![](https://mms.businesswire.com/media/20231018095054/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Present at Upcoming Investor Conferences
October 18, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20231016304311/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
October 16, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20231013777215/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
October 13, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20231013811765/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20231011998796/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20231011336627/en/1912146/22/OpzeluraTube_MOC_11October2023.jpg)
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
October 11, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20231010468675/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20231010367576/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report Third Quarter Financial Results
October 10, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230929594890/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
September 29, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230822167395/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conferences
August 22, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230731698519/en/1855034/22/Picture1.jpg)
![](https://mms.businesswire.com/media/20230711230393/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20230711569566/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report Second Quarter Financial Results
July 11, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230525005514/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20230518005001/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conferences
May 23, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230508005263/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
May 08, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230502005266/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 02, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230501005479/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20230420005667/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20230418005078/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conferences
April 18, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230411005060/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report First Quarter Financial Results
April 11, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230326005073/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20230323005785/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20230322005618/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20230306005672/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20230303005316/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20230216005010/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
February 16, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230210005205/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
February 10, 2023
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20230207005303/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20230124005025/en/1078784/22/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
January 24, 2023
From Incyte
Via Business Wire
Tickers
INCY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.